Brief: Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress
28/10/2025 12:50
Oct 28 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA PRESENTS LP-284 CLINICAL DATA AT 25TH LL&M CONGRESS, HIGHLIGHTING COMPLETE RESPONSE IN THERAPEUTICALLY EXHAUSTED DLBCL PATIENT & THERAPEUTIC POTENTIAL IN ADVANCED B-CELL CANCERS. Source text: ID:nBw8TG6w6a Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview